N-(1,1-dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alsoKnownAs |
gptkb:finasteride
|
| gptkbp:approvalYear |
1992
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
D11AX10
|
| gptkbp:CASNumber |
98319-26-7
|
| gptkbp:chemicalFormula |
C23H36N2O2
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:drugClass |
5α-reductase inhibitor
|
| gptkbp:eliminationHalfLife |
4.8-6 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
N-(1,1-dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
|
| gptkbp:IUPACName |
N-tert-butyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
372.549 g/mol
|
| gptkbp:PubChem_CID |
57363
CHEMBL452 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
decreased libido
erectile dysfunction ejaculation disorder |
| gptkbp:UNII |
57GNO57U7G
|
| gptkbp:usedFor |
treatment of benign prostatic hyperplasia
treatment of male pattern baldness |
| gptkbp:bfsParent |
gptkb:finasteride
|
| gptkbp:bfsLayer |
6
|